Success Metrics

Active Trials
5(38%)

Phase Distribution

Ph early_phase_1
7
54%
Ph phase_1
6
46%

Phase Distribution

13

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
7(53.8%)
Phase 1Safety & dosage
6(46.2%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

13

all time

Status Distribution
Active(7)
Terminated(1)
Other(5)

Detailed Status

unknown5
Recruiting4
Not yet recruiting2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
5
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 17 (53.8%)
Phase 16 (46.2%)

Trials by Status

withdrawn18%
unknown538%
not_yet_recruiting215%
active_not_recruiting18%
recruiting431%

Recent Activity

5 active trials
Showing 5 of 13
recruitingphase_1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269
active_not_recruitingphase_1

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

NCT06530849
recruitingearly_phase_1

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

NCT05858684
recruitingearly_phase_1

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

NCT07058298
not_yet_recruitingearly_phase_1

GC012F in Patients With Autoimmune Diseases

NCT07072884
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07250269Phase 1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Recruiting
NCT06530849Phase 1

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Active Not Recruiting
NCT05858684Early Phase 1

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Recruiting
NCT07058298Early Phase 1

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Recruiting
NCT07072884Early Phase 1

GC012F in Patients With Autoimmune Diseases

Not Yet Recruiting
NCT06419166Early Phase 1

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

Withdrawn
NCT06759948Phase 1

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Not Yet Recruiting
NCT05840107Early Phase 1

Study of FasT CAR-T GC012F Injection NDMM Patients

Recruiting
NCT05846347Phase 1

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Unknown
NCT04935580Phase 1

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Unknown
NCT05412329Phase 1

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Unknown
NCT04617704Early Phase 1

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Unknown
NCT04236011Early Phase 1

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13